公开(公告)号：US11638706B2

公开(公告)日：2023-05-02

申请号：US17093194

申请日：2020-11-09

申请人： PTC Therapeutics, Inc.

发明人： Suresh Babu ,  Anuradha Bhattacharyya ,  Seongwoo Hwang ,  Minakshi Jani ,  Young-choon Moon ,  Nadiya Sydorenko

IPC分类号： C07D417/14 ,  A61K31/4468 ,  A61K31/506 ,  A61K31/433 ,  C07D403/14 ,  C07D405/14 ,  C07D401/12 ,  C07D417/04 ,  C07D487/04 ,  C07D401/04 ,  C07D409/14 ,  C07D487/10 ,  C07D237/20 ,  C07D471/10 ,  C07D413/14 ,  C07D487/08 ,  C07D405/12 ,  C07D403/10 ,  C07D471/08 ,  C07D403/12 ,  C07D417/10 ,  C07D401/14 ,  C07D417/12 ,  A61K31/50 ,  A61K31/415 ,  A61P25/28 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5513 ,  G01N33/68

摘要： The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

公开(公告)号：US20230117508A1

公开(公告)日：2023-04-20

申请号：US18063907

申请日：2022-12-09

申请人： ALTO NEUROSCIENCE, INC.

发明人： Amit ETKIN ,  Dan SEGAL ,  Maria FERREIRA DA SILVA ,  Lauren BLAKE

IPC分类号： A61K31/4468 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/519 ,  A61P25/00

摘要： The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT4 agonist, an H3 antagonist or inverse agonist, a nicotinic α7 receptor agonist, a β3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

公开(公告)号：US20230102206A1

公开(公告)日：2023-03-30

申请号：US17909302

申请日：2021-03-04

申请人： The Trustees of Columbia University in the City of New York

发明人： Dalibor Sames ,  Vaclav Havel

IPC分类号： A61K31/55 ,  A61K31/485 ,  A61K31/451 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/137 ,  A61K31/135 ,  A61K31/4375 ,  A61K31/437 ,  A61K31/554 ,  A61P25/36 ,  A61P25/24 ,  A61P25/16

摘要： The present invention provides a composition which comprises a compound which is a mixture of deuterium containing and non-deuterium containing molecules having the structure: wherein R1 is wherein at least one of H1, H2 or H3 is a deuterium-enriched —H site, or wherein at least one of H1, H2, H3, H4 or H5 is a deuterium-enriched —H site, or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorders, and opioid withdrawal symptoms.

公开(公告)号：US20230090417A1

公开(公告)日：2023-03-23

申请号：US17950802

申请日：2022-09-22

申请人： Iolyx Therapeutics, Inc.

发明人： Elizabeth W. Jeffords ,  Hovhannes John Gukasyan ,  Rozemarijn Verhoeven ,  Houman David Hemmati ,  Daniel J. Estes

IPC分类号： A61K31/4468 ,  A61K31/335 ,  A61K31/573 ,  A61P27/02

摘要： The present invention relates to methods of treating ocular inflammatory diseases by administering ophthalmic pharmaceutical compositions of roflumilast. Administration of ophthalmic pharmaceutical compositions of roflumilast can provide significant immunomodulatory and anti-inflammatory activity relative to existing immunomodulatory, immunosuppressant, or non-steroidal anti-inflammatory therapies, including corticosteroids and antihistamines, while also providing an improved safety and convenience profile relative to one or both agents.

公开(公告)号：US20230054379A1

公开(公告)日：2023-02-23

申请号：US17788815

申请日：2020-12-18

申请人： Centro de Investigacion Y Desarrollo de Medicamentos (CIDEM)

发明人： Bárbara Beatriz GARRIDO SUÁREZ ,  Pedro Gilberto BÁRZAGA FERNÁNDEZ ,  Alejandro Saúl PADRÓN YAQUIS ,  Yamila VERDECIA REYES ,  Estael OCHOA RODRIGUEZ

IPC分类号： A61K31/5513 ,  A61K31/485 ,  A61K31/135 ,  A61K31/439 ,  A61K31/55 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4535 ,  A61K31/4465 ,  A61K31/137 ,  A61K31/222 ,  A61P25/04

摘要： The present invention describes a pharmaceutical composition that includes a novel molecule with neuroprotective activity, to inhibit the neuroadaptations induced by opioids (tolerance and hyperalgesia) that lead to the successive escalation of its doses in the treatment of pain. In this way, it increases its analgesic efficacy in normal conditions and in neural damage, since this favors the appearance of tolerance/hyperalgesia and resistance to opioid treatment. Likewise, reduce the spontaneous signs of withdrawal associated with its withdrawal and consequently physical dependence and possible addiction. In addition, it describes a method for the treatment of pain with a neuropathic component that is supported by drug interaction and safety studies that show its synergy for the mechanical antihypernociceptive effect.

公开(公告)号：US11491232B2

公开(公告)日：2022-11-08

申请号：US16489238

申请日：2018-03-29

申请人： Fruithy Holdings Limited

发明人： Shanchun Zhang ,  Jiashi Peng ,  Bin Yang ,  Yihua Wang ,  Min Xu ,  Xiao Wang ,  Kaisheng Cheng

IPC分类号： A61K47/54 ,  A61K31/52 ,  A61K31/505 ,  A61K31/573 ,  A61K31/4035 ,  A61K31/4164 ,  A61P1/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K31/4468

摘要： The present disclosure relates to the field of pharmaceutical chemistry, and particularly to a compound represented by Formula (I), a preparation method and medical use thereof. In the compound represented by Formula (I), a lactulosyl group is connected to a heteroatom of genin (G) via a glycosidic bond, wherein the genin (G) is a group formed by removing one hydrogen atom from a heteroatom of an active pharmaceutical molecule, and “” indicates that the lactulosyl group is connected to the heteroatom of the genin (G) via an α-glycosidic bond or a β-glycosidic bond. Pharmacokinetic experiments prove that the lactuloside compound according to the present disclosure can pass through the gastrointestinal tract of a mammal without being absorbed significantly by the gastrointestinal tract and hydrolyzed significantly by endogenous enzymes of a mammal host. Therefore, the lactuloside compound can arrive at the colon site of the mammal, and release an active drug in the colon under the action of colon flora. The lactuloside compound has a function of colon-localized drug release, and can be used for preventing or treating an intestinal disease.

公开(公告)号：US11491152B2

公开(公告)日：2022-11-08

申请号：US17700947

申请日：2022-03-22

申请人： BOW RIVER LLC

发明人： Sundar Srinivasan ,  Christina Chow Wallen

IPC分类号： A61K31/496 ,  A61P35/00 ,  A61P35/02 ,  A61P25/18 ,  A61P25/16 ,  A61P35/04 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/4468 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395

摘要： The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

公开(公告)号：US20220339145A1

公开(公告)日：2022-10-27

申请号：US17740624

申请日：2022-05-10

申请人： Texas Tech University System

发明人： Sanjay K. Srivastava ,  Sharavan Ramachandran

IPC分类号： A61K31/4468 ,  A61K31/506 ,  A61K45/06 ,  A61P35/00

摘要： The present invention includes composition and methods for treating cancers comprising administering to a subject a pharmaceutical composition comprising Pimavanserin, active polymorphs, or salts thereof in an amount sufficient to treat the cancer in the subject and a pharmaceutically acceptable carrier.

公开(公告)号：US20220288048A1

公开(公告)日：2022-09-15

申请号：US17629098

申请日：2020-07-22

申请人： ACADIA Pharmaceuticals Inc.

发明人： Dragana Bugarski Kirola ,  Ethan S. Burstein

IPC分类号： A61K31/4468 ,  A61P25/18

摘要： The present disclosure relates generally to therapeutic use of pimavanserin or a pharmaceutical acceptable salt thereof. More specifically, the present disclosure provides methods for treating schizophrenia by administering pimavanserin or a pharmaceutical acceptable salt thereof as an adjunct therapy in a patient who has an inadequate response to another antipsychotic therapy.

公开(公告)号：US11439807B2

公开(公告)日：2022-09-13

申请号：US16657147

申请日：2019-10-18

申请人： LTS Lohmann Therapie-Systeme AG

发明人： Mohammad Sameti ,  Ronald Hackbarth ,  Klaus Schumann ,  Christoph Schmitz

IPC分类号： A61N1/04 ,  A61K31/27 ,  A61K31/4468 ,  A61K31/485 ,  A61K31/55 ,  A61K38/22 ,  A61K38/27 ,  A61K38/28 ,  A61K38/36 ,  A61M37/00 ,  A61N1/30

摘要： The invention relates to a transdermal therapeutic system (TTS) for delivering pharmaceutical active ingredients. The TTS includes a cover layer and at least one active-ingredient-containing carrier material. At least one retaining element is located between the active-ingredient-containing carrier material and the cover layer, with the retaining element fixing the active-ingredient-containing carrier material onto the cover layer. The invention further relates to a method for fastening an active-ingredient-containing carrier material to a cover layer of a TTS in the presence of hook-and-loop strip segments and the use of a hook-and-loop strip in transdermal or iontophoretic administration of pharmaceutical or therapeutic active ingredients to patients.